Prosecution Insights
Last updated: April 19, 2026

Fate Therapeutics Inc.

8 pending office actions

Portfolio Summary

8
Total Pending OAs
3
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18917836 EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS FAUST, AMBER KATHLEEN 1643 Non-Final OA Oct 16, 2024
18501627 COMPOSITION AND METHODS FOR INDUCING MYELOID SUPPRESSIVE CELLS AND USE THEREOF O'NEILL, MARISOL ANN 1633 Non-Final OA Nov 03, 2023
18028457 ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS GODDARD, LAURA B 1642 Non-Final OA Mar 24, 2023
17782600 ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS WESTON, ALYSSA G 1633 Final Rejection Jun 03, 2022
17769651 ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF ZHU, JIANJIAN 1631 Non-Final OA Apr 15, 2022
17762693 MULTI-TARGETING EFFECTOR CELLS AND USE THEREOF MATALKAH, FATIMAH KHALAF 1638 Final Rejection Mar 22, 2022
17438317 CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS GONZALES, JOSEPHINE MARIA 1631 Final Rejection Sep 10, 2021
17040951 ENGINEERED IMMUNE EFFECTOR CELLS AND USE THEREOF DHAR, MATASHA 1632 Non-Final OA Sep 23, 2020

Managing Fate Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month